ClinicalTrials.Veeva

Menu
C

California Allergy and Asthma Medical Group | Los Angeles, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Dupilumab
HFA
Ciclesonide Hydrofluoroalkane
Omalizumab
Camoteskimab
PF-03715455
Symbicort®
Mometasone
Rezpeg

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 24 total trials

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: Matching placebo
Biological: barzolvolimab

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Enrolling
Chronic Inducible Urticaria
Drug: Oral EVO756

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Enrolling
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Placebo
Drug: Camoteskimab

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.The purpo...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Amlitelimab

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed al...

Enrolling
Allergy, Peanut
Drug: placebo
Drug: remibrutinib

Trial sponsors

C
AbbVie logo
Pfizer logo
Sanofi logo
Sumitomo Pharma logo
A
A
Celldex Therapeutics logo
E
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems